|
Q1 FY2027
As of Jun 30, 2026
|
Q4 FY2026
As of Mar 31, 2026
|
Q3 FY2026
As of Dec 31, 2025
|
Q2 FY2026
As of Sep 30, 2025
|
Q1 FY2026
As of Jun 30, 2025
|
Q4 FY2025
As of Mar 31, 2025
|
Q3 FY2025
As of Dec 31, 2024
|
Q2 FY2025
As of Sep 30, 2024
|
Q1 FY2025
As of Jun 30, 2024
|
Q4 FY2024
As of Mar 31, 2024
|
Q3 FY2024
As of Dec 31, 2023
|
Q2 FY2024
As of Sep 30, 2023
|
Q1 FY2024
As of Jun 30, 2023
|
Q4 FY2023
As of Mar 31, 2023
|
Q3 FY2023
As of Dec 31, 2022
|
Q2 FY2023
As of Sep 30, 2022
|
Q1 FY2023
As of Jun 30, 2022
|
Q4 FY2022
As of Mar 31, 2022
|
Q3 FY2022
As of Dec 31, 2021
|
Q2 FY2022
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Research and development incentives receivable | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Research and development incentives receivable, non-current | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Other non-current assets | ||||||||||||||||||||
| Right-of-use asset - operating leases | ||||||||||||||||||||
| Right-of-use asset - finance leases | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders' Equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Operating lease liabilities, current | ||||||||||||||||||||
| Finance lease liabilities, current | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Operating lease liabilities, non-current | ||||||||||||||||||||
| Finance lease liabilities, non-current | ||||||||||||||||||||
| Long term debt, net of discount | ||||||||||||||||||||
| Other liabilities, non-current | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity | ||||||||||||||||||||
| Common stock, $0.001 par value; 150,000,000 shares authorized as of June 30, 2026 and March 31, 2026; 83,979,366 and 82,716,923 shares issued and outstanding as of June 30, 2026 and March 31, 2026, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity |
Loading...
